4 news items
Tarsus to Participate in Upcoming Investor Conferences
TARS
29 May 24
is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
TARS
9 May 24
in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment
Analyst Ratings For Tarsus Pharmaceuticals
TARS
9 May 24
candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
TARS
1 May 24
as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet
- Prev
- 1
- Next